Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 - 58 (Cancelled)

59. (Currently Amended) A method of reducing risk of, ~~preventing~~ or treating, non-proliferative diabetic retinopathy and/or macular edema, in a mammal by administrating an effective amount of a medicament comprising at least one compound capable of inhibiting the visual cycle, to said mammal, wherein the at least one compound comprises a retinoid of the formula V:



(formula V),

wherein R1, R4, R9, R10 and R12 is CH3, and R3, R5, R6, R7, and R8 is H, and

wherein R11 is selected from the group consisting of:

-COOH,

- an alcohol group,

-CHO,

-CH2OCOCH2Br,

-CH2OCOCH2Cl,

-COOCH2CH3,

-CONHR', wherein R' is 4-hydroxy-phenyl or ethyl, and

-COOR", wherein R" is beta-D-glucuronide, and wherein the configuration of the four isoprenoid units is all trans (E) or one or more is cis (Z), with the proviso that when R11 is -COOH, the configuration is not 9 cis (2E, 4E, 6Z 8E) or all trans.

60. (Previously Presented) The method of claim 59, wherein said mammal is a human being.

61. (Previously Presented) The method of claim 59, wherein said mammal has been diagnosed with diabetes.

62-78. (Cancelled)

79. (Currently Amended) The method of claim 59, wherein the at least one compound comprises a compound selected from the group consisting of: isotretinoin (13-*cis*-retinoic acid), 11-*cis*-retinol, 11-*cis*-retinal, 11-*cis*-retinyl bromoacetate, ~~acitretin, etretinate,~~ fenretinide, ~~4-oxo-isotretinoin, motretinide,~~ retinaldehyde, *all-trans*-retinyl bromoacetate, *all-trans*-retinyl chloroacetate, and retinoyl betaglucoronide.

80-107. (Cancelled)

108. (Previously Presented) The method of claim 59, wherein the at least one compound is composed as a pro-drug.

109. (Previously Presented) The method of claim 59, wherein the medicament is in a form for being administered locally.

110. (Previously Presented) The method of claim 109, wherein the medicament is in a form for being administered intravitreally.

111. (Previously Presented) The method of claim 59, wherein the medicament is in device formulation held confined by mechanical or physico-chemical effects.

112. (Previously Presented) The method of claim 59, wherein the medicament is in a slow-release formulation.

113. (Previously Presented) A method comprising a pharmaceutical composition suitable for intravitreal implantation comprising a pharmaceutically effective amount of at least one compound capable of inhibiting the visual cycle and/or dark adaptation.

114. (Previously Presented) The method of claim 113, wherein said pharmaceutically effective amount of said at least one compound is determined by measuring the level of reduction of dark adaptation in a treated subject.

115. (Previously Presented) The method of claim 113, wherein said pharmaceutical composition is in device formulation held confined by physico-chemical effects.

116. (New). The method of claim 59 which is a method of treating non-proliferative diabetic retinopathy and/or macular edema.

117. (New). The method of claim 59 which is a method of treating non-proliferative diabetic retinopathy.

118. (New). The method of claim 59 wherein the alcohol group is $-CH_2OH$.